Novo Nordisk Patient Support During Wegovy Shortage

Introduction

Novo Nordisk operates several patient support programs that can help during Wegovy® supply gaps: NovoCare direct cash channel, savings cards for insured patients, the Patient Assistance Program for uninsured, and the Wegovy Stock Locator tool. This piece covers what each does and when to use which.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is NovoCare DiRECT?

NovoCare Pharmacy is Novo Nordisk’s direct-to-consumer cash channel for Wegovy, launched in March 2025. It ships Wegovy directly to U.S. patients at $499 per month for any approved strength.

Quick Answer: NovoCare direct ships Wegovy for $499 per month cash pay to uninsured patients

The program is meant for patients without insurance coverage for Wegovy. Patients with insurance coverage are generally directed back to traditional pharmacy channels. The portal verifies prescription status and ships through a contracted specialty pharmacy.

NovoCare has its own supply chain separate from retail pharmacies. When retail is tight, NovoCare typically still ships within 7 to 12 business days from prescription verification.

The $499 monthly price is roughly a third of typical retail cash prices, which can run $1,000 to $1,400 per month for Wegovy.

How Does the Wegovy Savings Card Work?

The Wegovy Savings Card reduces commercial-insurance copays for eligible patients. As of 2026, the savings card can bring eligible copays to as low as $0 per month for patients with commercial insurance that covers Wegovy.

Eligibility requires commercial insurance coverage of Wegovy (any tier). Medicare, Medicaid, and government insurance patients are not eligible. The card caps savings at $225 per fill and $500 per fill for some programs, with annual caps that vary by plan.

To use the card, register at wegovy.com, get a savings card number, and present it at the pharmacy along with your insurance card. The pharmacy processes both, with the savings card applied as a secondary payer to reduce your out-of-pocket cost.

The card does not change pharmacy stock or supply. If your pharmacy doesn’t have Wegovy, the savings card doesn’t help find it. But for patients with high copays, the card reduces the cost meaningfully.

What Is the Novo Nordisk Patient Assistance Program?

The Patient Assistance Program (PAP) provides Wegovy at no cost to U.S. patients who meet income thresholds and don’t have insurance coverage for the drug. Income criteria are generally 400% of the federal poverty level (around $60,000 for a single person, $124,000 for a family of four in 2026).

Eligibility requires U.S. residency, a valid Wegovy prescription, no insurance coverage of Wegovy, and documentation of income. The application asks for tax returns or pay stubs to verify financial status.

If approved, Wegovy is shipped at no cost typically every 90 days. Approval is for one year and requires re-application annually.

The PAP is separate from NovoCare cash pay. Both serve uninsured patients but have different eligibility and pricing structures. PAP is free for qualifying patients. NovoCare is $499 per month with no income requirements.

How Does the Wegovy Stock Locator Work?

The Stock Locator at wegovy.com is a tool that shows pharmacy-level Wegovy inventory based on data from Novo Nordisk’s wholesale and pharmacy network. It refreshes every few hours.

To use it, enter your ZIP code and the dose strength you need. The tool displays nearby pharmacies with color-coded indicators showing whether they have stock, are low, or are out.

Limitations: pharmacy stock changes hour by hour, so the locator’s data can be 1 to 4 hours out of date. Always call the pharmacy directly to confirm before going. The locator is most useful for filtering out clearly empty pharmacies and identifying ones likely to have stock.

The locator differentiates by strength. The 0.25 mg starter pen usually shows widespread availability. The 1.7 mg and 2.4 mg maintenance pens show fewer green dots in 2026.

How Does Novo’s Patient Support Handle Prior Authorization Issues?

The Novo Nordisk patient support team can help with PA escalation. If your insurance has denied or delayed Wegovy approval, calling the patient support line (1-833-4-WEGOVY) connects you with staff who can:

• Provide PA submission templates and clinical documentation
• Help your prescriber compose appeal letters
• Coordinate with your insurance plan’s clinical review team
• Identify alternative coverage pathways through state programs

The support team doesn’t bypass PA requirements, but they help patients and prescribers complete documentation correctly. PA denial rates for Wegovy with proper documentation are lower than denial rates without support.

For patients who have been denied and need to appeal, Novo Nordisk publishes appeal letter templates and clinical reference documents at wegovy.com/coverage.

Key Takeaway: The Novo Nordisk Patient Assistance Program covers Wegovy at zero cost for patients meeting income thresholds (generally 400% of federal poverty level)

What’s NovoCare’s Relationship to Insurance?

NovoCare cash pay is designed for patients without Wegovy insurance coverage. Patients with insurance are generally not eligible for NovoCare and are directed back to traditional retail or mail-order channels.

The eligibility check happens at portal registration. If your insurance covers Wegovy, the portal may decline your NovoCare application and refer you to your insurance plan.

This separation matters because NovoCare is priced as a cash benefit for uninsured patients, not as a workaround for insurance. Stacking NovoCare with insurance is not allowed.

For insured patients facing supply gaps at retail, mail-order through your insurance plan’s pharmacy benefit manager is the right channel. For uninsured patients, NovoCare or the PAP (if eligible) are the right channels.

What About Insurance Appeals?

If your insurance denies Wegovy coverage, you have appeal rights under federal and state insurance regulations. The Novo Nordisk patient support team can help with appeal documentation.

Typical appeal pathway:

1. Submit initial appeal in writing within the time limit (usually 30 to 60 days from denial)
2. Include clinical documentation showing BMI, comorbidities, prior weight-loss attempts, and prescriber rationale
3. Reference clinical trial data (STEP 1 for obesity, SELECT for cardiovascular indication)
4. Submit any specific exclusion or coverage criteria your plan cites
5. If denied, escalate to external review (independent third-party review)

Appeal success rates vary by plan and indication. SELECT-based cardiovascular indication appeals have higher approval rates than obesity-only appeals because cardiovascular coverage is more standardized across plans.

How Does Novo’s Support Differ From Third-party Patient Advocacy?

Novo Nordisk’s patient support is funded by the manufacturer and focuses on Wegovy specifically. Independent patient advocacy groups (like the Obesity Action Coalition) provide broader support across multiple drugs and conditions.

For Wegovy-specific issues (stock, coverage, savings cards), Novo’s support team is the right resource. For broader obesity treatment advocacy, condition support, or comparing multiple drug options, third-party advocacy can be more complete.

Both can be useful for different parts of the patient journey.

What Does Novo Nordisk’s Manufacturing Investment Mean for Patients?

Novo invested more than $6 billion in semaglutide capacity expansion through 2025, including the $16.5 billion Catalent acquisition completed in late 2024. The investment is targeted at fill-finish capacity for higher-dose Wegovy pens (1.7 mg and 2.4 mg), which are the slowest to normalize at retail.

For patients, the manufacturing investment translates to:

• Reduced backorder frequencies through Q3 and Q4 2026
• More consistent stock at maintenance doses by 2027
• Continued capacity for new patient starts at lower doses

Novo’s Q1 2026 guidance projected that 2.4 mg supply would reach normalized retail availability in Q1 to Q2 2027.

Bottom line: Novo’s patient support team can assist with prior authorization escalation and appeals

FAQ

Can I Use NovoCare If I Have Medicare?

Yes, as cash pay. Medicare beneficiaries can use NovoCare as cash pay outside their Medicare coverage. Payments don’t apply to Part D deductibles.

Does the Savings Card Work for Off-label Use?

No. The savings card requires on-label use for obesity or cardiovascular indication, with proof of commercial insurance coverage.

How Long Does the PAP Application Take?

Typically 4 to 6 weeks from application submission to approval. Bridge supply through NovoCare or retail may be needed during the gap.

Is There a TrimRx Connection to Novo Nordisk Programs?

No direct relationship. TrimRx focuses on compounded semaglutide through state-licensed pharmacies. Novo Nordisk programs cover brand Wegovy. Patients can use either or both depending on their situation.

Will the Savings Card Expire?

The card has annual caps and the program is renewed yearly by Novo Nordisk. The card can be reissued each year for continuing eligible patients.

Does Novo’s Support Help with Switching to Zepbound®?

Not directly. Novo’s support is Wegovy-focused. Switching to Zepbound (an Eli Lilly product) goes through Lilly’s support and your prescriber.

What If I’m Denied for the PAP?

You can re-apply if your financial situation changes. NovoCare cash pay at $499 per month remains an option without income requirements.

How Does Novo Nordisk Track Patient Outcomes?

The company publishes ongoing real-world evidence studies on Wegovy outcomes through peer-reviewed journals. Individual patient outcomes aren’t tracked by Novo unless patients participate in formal studies.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.